Tag: Rubius Therapeutics

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. posted a loss of $48.5 million for the first quarter of 2020, or a loss of 60 cents...

PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018. Loss per diluted share...

CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company...

PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...

RI BIO, a Providence-based biotechnology trade association, is on a mission to put Rhode Island on the biotech industry’s map. Despite the state having...

PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases,...

SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share,...

PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality...

SMITHFIELD – Biotechnology firm Rubius Therapeutics Inc. was added to the Nasdaq biotechnology index on Dec. 24. The company, based in Cambridge, Mass., but building...

PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an...